Hepatitis B Virus
Adefovir dipovixil provides relief in lamivudine-resistant HBeAg-negative hepatitis B infections
Published in Hepatitis Weekly, November 28th, 2005
"ADV, a new nucleotide analogue, has demonstrated activity against lamivudine-resistant HBV both in vivo and in vitro. Herein, we present eight lamivudine-resistant patients with chronic anti-HBe positive hepatitis B treated orally with adefovir dipivoxil at 10 mg/day to evaluate the efficacy and safety of this drug and to determine the possible development of clinical ADV resistance," wrote G. Scotto and colleagues, University of Foggia.
"After 48 weeks of therapy, 4/8 (50%)...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2005-11-28)
More Articles from Hepatitis Weekly
- Genetics & Genomics
Hepatitis patients in Cameroon display heterogeneous hepatitis C genotypes - Hepatitis B Virus
E-cadherin expression represses via activation of DNA methyltransferase 1 - Hepatitis C Virus
Hepatitis C virus carriers with normal serum aminotransferase may need therapy within 5 years - Infectious Diseases
CTLA-4Ig suppresses liver injury by inhibiting acquired immune responses - Addiction Medicine
New findings in the area of addiction medicine described - Adverse Drug Reaction
Recent findings in adverse drug reaction described - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
